The factors associated with mild cognitive impairment in outpatient practice

Marija Lazarević; Dragan Milovanović; Dejana Ružić Zečević

doi:10.2298/VSP221107099L

Marija Lazarević Health Center “Dr. Milenko Marin”, Loznica, Serbia
Dragan Milovanović University of Kragujevac, Faculty of Medical Sciences, Department for Pharmacology, Kragujevac, Serbia
Dejana Ružić Zečević University of Kragujevac, Faculty of Medical Sciences, Department for Pharmacology, Kragujevac, Serbia

DOI: https://doi.org/10.2298/VSP221107099L

Ključne reči: saznanje, disfunkcija, komorbiditet, dijabetes mellitus, insulin nezavisni, rizik, procena, faktori rizika, vitamin b12

Sažetak

Uvod/Cilj. Prethodne studije pokazale su da je blago kognitivno oštećenje (BKO) češće kod bolesnika sa komorbiditetima, kao i kod bolesnika koji koriste lekove koji remete homeostazu vitamina B12. Cilj rada bio je da se utvrdi koji od tih faktora su značajno povezani sa BKO i koji su najznačajniji za predviđanje njegovog nastanka. Metode. Podaci o 200 odraslih osoba (starosti 35–65 godina) uključenih u kliničku studiju po tipu anamnestičke studije u ustanovi primarne zdravstvene zaštite su prikupljeni prospektivno. Rezultati. Primenom χ² testa nezavisnosti, utvrđeno je da da su BKO i upotreba inhibitora protonske pumpe (IPP) (p < 0,0005), kao i metformina (p < 0,0005), nezavisni faktori. Takođe, značajno viši procenat ispitanika koji su imali BKO su imali peptički ulkus i tip 2 dijabetes melitus (T2DM). Da bi se procenio uticaj mnogih faktora verovatnoće na to da li će ispitani bolesnici imati BKO primenjena je direktna logistička regresija. Dve varijable dale su statistički značajan doprinos modelu, a to su koncentracije vitamina B12 u serumu [odds ratio (OR) = 0,953; 95% confidence interval (CI) 0,936–0,971; p < 0,001] i T2DM (OR = 6,681; 95% CI 1,305–34,198; p = 0,023). Zaključak. Apsolutna i relativna povezanost rizika izloženosti lekovima sa BKO niža je od povezanosti komorbiditeta sa BKO. Koncentracije vitamina B12 u serumu i prisustvo T2DM imaju najveći statistički značajan uticaj na predviđanje BKO.

Reference

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 270–9.

2. Brusselaers N, Lagergren J. The Charlson comorbidity index in registry-based research. Methods Inf Med 2017; 56(05): 401–6.

3. Canevelli M, Remoli G, Toccaceli Blasi M, Tariciotti L, Sarli G, Valletta M, et al. Ongoing Research Protocols for the Pharmacological Treatment of Neuropsychiatric Symptoms in Dementia. J Frailty Aging 2021; 10(1): 22–30.

4. Liss JL, Seleri Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, et al. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med 2021; 290(2): 310–34.

5. Markun S, Gravestock I, Jäger L, Rosemann T, Pichierri G, Burgstaller ЈM. Effects of vitamin B12 supplementation on cognitive function, depressive symptoms, and fatigue: a systematic review, meta-analysis, and meta-regression. Nutrients 2021; 13(3): 923.

6. Miller ЈW. Proton Pump Inhibitors, H2-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications. Adv Nutr 2018; 9(4): 511S–8S.

7. Deng Y, Zhao S, Cheng G, Yang J, Li B, Xu K, et al. The prevalence of mild cognitive impairment among Chinese people: a meta-analysis. Neuroepidemiology 2021; 55(2): 79–91.

8. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189–98.

9. Chertkow H, Massoud F, Nasreddine Z, Belleville S, Joanette Y, Bocti C, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 2008; 178(10): 1273–85.

10. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9(3): 179–86.

11. Martínez-Horta S, Bejr-Kasem H, Horta-Barba A, Pascual-Sedano B, Santos-García D, Jesús S, et al. Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson’s disease. BMC Neurol 2021; 21(1): 477.

12. Salama II, Sami SM, Abdellatif GA, Mohsen A, Rasmy H, Kamel SA, et al. Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus. PLoS One 2020; 15(7): e0236453.

13. Silay K, Yalcin A, Akinci S, Gursoy FG, Sener Dede D. Charlson Comorbidity Index, inappropriate medication use and cognitive impairment: Bermuda Triangle. Wien Klin Wochenschr 2017; 129(21–22): 799–804.

14. Serin E, Gümürdülü Y, Özer B, Kayaselçuk F, Yilmaz U, Koçak R. Impact of Helicobacter pylori on the development of vitamin B12 deficiency in the absence of gastric atrophy. Helicobacter 2002; 7(6): 337–41.

15. Ma F, Wu T, Zhao J, Ji L, Song A, Zhang M, et al. Plasma homocysteine and serum folate and vitamin B12 levels in mild cognitive impairment and Alzheimer’s disease: a case-control study. Nutrients 2017; 9(7): 725.

16. Sakyi SA, Laing EF, Mantey R, Kwarteng A, Owiredu EW, Dadzie RE, et al. Profiling immuno-metabolic mediators of vitamin B12 deficiency among metformin-treated type 2 diabetic patients in Ghana. PLoS One 2021; 16(3): e0249325.

17. Urbanski G, Villoteau A, Lozac’h P, N’guyen M, Schlumberger E, Beucher АB, et al. Carence en vitamine B12, metformine et inhibiteurs de pompe à protons. Rev Med Interne 2017; 38: A54–5. (French)

18. Ferri F, Deschênes SS, Power N, Schmitz N. Association between depressive symptoms, metabolic risk factors, and cognitive function: cross-sectional results from a community study in Quebec, Canada. Aging Ment Health 2021; 25(11): 2003–10.

19. Pal K, Mukadam N, Petersen I, Cooper C. Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 2018; 53(11): 1149–60.

20. Cardoso S, Moreira PI. Diabesity and brain disturbances: A metabolic perspective. Mol Aspects Med 2019; 66: 71–9.

21. Makino K, Lee S, Bae S, Chiba I, Harada K, Katayama O, et al. Diabetes and Prediabetes Inhibit Reversion from Mild Cognitive Impairment to Normal Cognition. J Am Med Dir Assoc 2021; 22(9): 1912–8.

22. Kimura AM, Kinnno R, Tsuji M, Ono K. Effects of vitamin B12 on cognitive function in elderly patients. J Alzheimer Assoc 2021; 17: e055458.

23. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101(4): 1754–61.

24. Alam MS, Kamrul-Hasan A, Kalam ST. Serum vitamin B12 status of patients with type 2 diabetes mellitus on metformin: A single-center cross-sectional study from Bangladesh. J Family Med Prim Care 2021; 10(6): 2225–9.

25. Bell DSH. Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes Obes Metab 2022; 24(8): 1423–8.

Faktori povezani sa blagim kognitivnim oštećenjem kod ambulantno lečenih bolesnika

Sažetak

Reference